News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Shareholders Approve Buyback as Royalty Pharma Fight Heats Up


4/12/2013 7:12:37 AM

Irish drugmaker Elan won strong approval from shareholders for a $1 billion share buyback as it seeks to keep them on side and stave off a takeover approach from U.S. investment firm Royalty Pharma. The buyback, priced between $11.25 and $13.00 per share, was supported by 99.2 percent of shareholders on Friday. The company was returning cash to investors after the $3.2 billion sale of its interest in multiple sclerosis drug Tysabri. Royalty may sweeten its $11 per share proposal by paying more via a contingent value right (CVR) if Tysabri, which Elan still receives royalties for, hits certain sales milestones, two people familiar with the matter told Reuters.

Read at Reuters
Read at Irish Times
Read at Bloomberg
Read at Nasdaq

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES